Short Information | Cyteir Therapeutics Inc. (NASDAQ:CYT)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 269,825 |
Total Actual Volume | 6,612,039 |
Short Trends | |
---|---|
Cover Days | 19 |
Short Days | 0 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 13,491 |
Average Short Percentage | 10.57% |
Is there a CYT Short Squeeze or Breakout about to happen?
See the CYT Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
03-15-2024 | $3.03 | $3.02 | $3.09 | $3 | 1,006,884 | 38,841 | 3.86% |
03-14-2024 | $3.02 | $3.09 | $3.09 | $3.02 | 153,115 | 6,037 | 3.94% |
03-13-2024 | $3.02 | $3.02 | $3.05 | $2.9999 | 227,464 | 14,781 | 6.5% |
03-12-2024 | $3.03 | $3 | $3.04 | $3 | 89,148 | 13,052 | 14.64% |
03-11-2024 | $3.15 | $3.03 | $3.15 | $3 | 3,462,934 | 34,365 | 0.99% |
03-08-2024 | $3.09 | $3.11 | $3.14 | $2.99 | 763,674 | 68,189 | 8.93% |
03-07-2024 | $3.05 | $3.04 | $3.08 | $3.04 | 81,611 | 366 | 0.45% |
03-06-2024 | $3.07 | $3.05 | $3.09 | $3.04 | 79,485 | 841 | 1.06% |
03-05-2024 | $3.08 | $3.07 | $3.085 | $3.06 | 37,187 | 2,449 | 6.59% |
03-04-2024 | $3.08 | $3.07 | $3.09 | $3.06 | 162,575 | 6,942 | 4.27% |
03-01-2024 | $3.11 | $3.1 | $3.13 | $3.08 | 19,637 | 3,135 | 15.96% |
02-29-2024 | $3.13 | $3.11 | $3.1314 | $3.09 | 58,560 | 5,265 | 8.99% |
02-28-2024 | $3.1 | $3.1 | $3.14 | $3.09 | 26,777 | 2,111 | 7.88% |
02-27-2024 | $3.15 | $3.11 | $3.15 | $3.1 | 37,930 | 5,849 | 15.42% |
02-26-2024 | $3.1 | $3.15 | $3.15 | $3.08 | 50,206 | 20,563 | 40.96% |
02-23-2024 | $3.13 | $3.1 | $3.13 | $3.1 | 16,305 | 859 | 5.27% |
02-22-2024 | $3.09 | $3.12 | $3.12 | $3.09 | 28,609 | 6,714 | 23.47% |
02-21-2024 | $3.13 | $3.1 | $3.13 | $3.0801 | 27,660 | 3,945 | 14.26% |
02-20-2024 | $3.06 | $3.1 | $3.1 | $3.06 | 99,367 | 18,636 | 18.75% |
02-16-2024 | $3.11 | $3.06 | $3.12 | $3.06 | 182,911 | 16,885 | 9.23% |
News, Short Squeeze, Breakout and More Instantly...
Cyteir Therapeutics Inc. Company Name:
CYT Stock Symbol:
NASDAQ Market:
Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026 Cyteir Therapeutics, ...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department...
- Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy - Strategic prioritization of clinical development of CYT-0851 combination therapy for ovarian cancer, together with deferral of other development activities, is expected to extend cash ...